OBJECTIVES: Transcatheter aortic valve implantation is a well-recognized treatment option for high-risk patients with aortic stenosis. The femoral approach is possible in 80% of cases and remains the access of choice. When this approach is not feasible, other alternative routes have been proposed such as transapical, transaortic and subclavian. Transcarotid aortic valve implantation has been proposed as another direct vascular access. Its use is relatively new and still under evaluation.
INTRODUCTION
Transcatheter aortic valve implantation (TAVI) is a well-recognized treatment option for high-risk patients with aortic stenosis [1] . The femoral approach is feasible in approximately 80-70% of cases, with mainly the transapical and subclavian access offered as alternative routes. Recently, other alternative accesses have been proposed: transaortic, transcarotid and brachiocephalic artery [2] . The choice of the intervention mode should take into account the cardiac and extracardiac characteristics of the patient, the individual risk of surgery, which is assessed by the judgement of the Heart Team in addition to the scores, the feasibility of TAVI and the local experience. Transcarotid aortic valve implantation (TCAVI) is a new and valuable alternative route, which has already been described [3, 4] . It provides a direct route to the aortic valve and avoids any sternal or thoracic incision. It has already been extensively used in paediatric patients for aortic valve ballooning with excellent results [5] . Its use in high-risk patients with aortic stenosis not suitable for transfemoral valve implantation has to be carefully compared with other alternative access routes such as transapical, transaortic and brachiocephalic and subclavian routes. The French TAVI registry has recently reported excellent 30-day and 1-year outcomes in 96 patients who underwent TCAVI [3] .
Most other series report on either a single institution or small numbers of patients for TCAVI [6] [7] [8] [9] . In this article, we report the results of 3 French cardiovascular institutions using the TCAVI approach.
MATERIALS AND METHODS
All patients were prospectively entered into the French TAVI registry, which is a national registry database. All consecutive patients who underwent TCAVI, performed between January 2013 and November 2015, in France, at the University of Lorraine Brabois Hospital, the University Hospital of Lille and the Institute Mutualiste Montsouris in Paris were entered.
The procedures carried out on TAVI patients in the 3 centres are essentially the same, including multidetector computer tomography scan of the entire supra-aortic vessels and the entire aorta up to the femoral bifurcation. All patients also underwent a duplex ultrasound of the carotid arteries, coronary angiogram and echocardiography and pulmonary function tests for patients with pulmonary disease.
The 3D volume-rendered images are routinely used for the evaluation of the general morphology and tortuosity of the vessels and their relationship with the surrounding tissues. The optimal TAVI access route is selected individually, based on the multidetector computer tomography and the physiological evaluation of the patient. We follow the femoral access route as a first strategy, followed by alternative routes in cases of poor iliofemoral access. If the pulmonary function tests are abnormal, the TCAVI will be privileged over a transapical approach. We do not usually perform a transapical approach if the forced expiratory volume in 1 s is less than 0.8 l or less than 35% of the predicted value.
Several conditions must be met to be eligible for TCAVI. The common carotid artery should be at least 7 mm without tortuosity and without calcifications. Neither carotid artery should present stenosis more than 30% at any level. Ostia calcifications or calcification of the aortic arch are not a contraindication, provided that the internal diameter of the artery is 7 mm or more.
The left or right common carotid arteries can be used, with a preference for the left side, as it usually presents less tortuosity and provides more direct access to the aortic arch. We selected either the left or right carotid artery, depending on the preference of the local team, if both arteries are accessible. It also depends on the placement of the fluoroscopy camera and the anaesthesiology ventilator with regard to the head.
In cases of previous strokes, an injected brain computed tomography scan or magnetic resonance imaging is performed searching for a patent circle of Willis or any evidence of embolic strokes. If cases of embolic strokes are related to any carotid plaques, or if the preoperative computed tomography scan or magnetic resonance imaging reveals previous strokes accompanied by carotid calcifications, then another route, other than the transcarotid route, is chosen.
In the event that pulmonary function tests are normal, the operating team will make a decision regarding the access route and the choice of a transapical or trans-subclavian or transaortic is assessed, which depends on each surgical team and experience.
The transcarotid approach is an alternative route to the transfemoral route but is neither the second nor the last choice in the 3 teams participating in the study.
Procedure and surgical technique
As previously described by our team [4] , the procedure is performed under general anaesthesia with continuous cerebral oximetry monitoring by means of bilateral cerebral tissue oxygen saturation measurement with the near infrared spectroscopy (NIRS) cerebral oximeter (Covidien, Dublin, Ireland).
A transverse incision of 4-5 cm, 2 fingerbreadths above and parallel to the clavicle, is performed to expose the common carotid artery. Dissection is made down through the platysma, exposing the omohyoid strap muscle and the sternocleidomastoid muscle. The muscles are retracted to expose the common carotid that is dissected away from the vagus nerve and jugular vein.
Two vessel loops are placed and a 6-Fr introducer sheath is inserted to cross the aortic valve and to place a stiff wire, over which an exchange is made with the introduction of the delivery catheter according to the valve device chosen (14 or 18 Fr). The most distal vessel loop is tightened after placing the catheter to avoid any possible embolization.
A small 30-Fr piece of a chest tube is cut and inserted over the delivery catheter at 8 cm to prevent any movement during the procedure (Fig. 1 ). This creates a stop on the delivery catheter, which prevents the device from being pushed too far into the aorta or ventricle, and also provides a certain degree of stability to the sheath, avoiding any lateral movement of the sheath. This technique is performed in the event that a balloon-expandable prosthesis is used; when a self-expandable prosthesis is used, the sheath is introduced via a counter incision made just above the neck incision to provide stability to the sheath. The rest of the TAVI procedure is performed per standard technique. The delivery catheter, wire and sheath are then removed after clamping of the distal common carotid artery. The carotid artery is closed with a double layer of 6-0 monofilament. Heparin is reversed and the neck is closed over a small drain. The platysma and skin layers are closed with absorbable braided suture.
Two types of prosthesis were used: a self-expandable valve in 121 (83.5%) patients and a balloon-expandable valve in 24 (16.5%) patients. 
Clinical end-points
Data concerning the end-points of device safety, 30-day clinical efficacy and time-related valve safety were prospectively collected, as defined by the Valve Academic Research Consortium (VARC)-2 criteria [10] . All patients were prospectively entered into the French TAVI national registry, as required by the French Ministry of Health.
RESULTS

Study population
TCAVI was performed in 145 consecutive patients. Table 1 summarizes the characteristics of patients. The mean age was 79.8 ± 8.7 years, 49 (33.8%) patients were men and all patients were at high risk for mortality if treated by conventional surgical aortic valve replacement (sAVR), with a mean logistic EuroSCORE of 20.7 ± 12.6%. All patients were in New York Heart Association functional Class III or IV. All patients were diagnosed with severe degenerative aortic valve stenosis; the aortic valve area ranged from 0.4 to 1.1 cm 2 , (mean 0.86 cm 2 ) with mean transvalvular gradients between 35 and 78 mmHg (mean 53.1 ± 12.5 mmHg), left ventricular ejection fraction ranged from 20% to 80% (mean 51.9 ± 12.2%).
All patients had excessively calcified or tortuous or small-calibre peripheral vessels, previous peripheral arterial interventions or a combination of pathologies. In addition, 32 (22%) patients had undergone coronary artery bypass grafting and most had proven patent grafts on angiography, either in situ left internal mammary artery grafts or vein grafts. All carotid arteries were large enough, as measured on multidetector computer tomography to introduce the sheath without complete occlusion.
Procedure feasibility
The transcarotid TAVI approach was successful in all patients. We did not experience any decrease in cerebral oximetry values. No conversion to full sternotomy was required. All valves were positioned correctly.
Early safety
Thirty-day survival was 93.75% (Table 2 ). Eight patients developed neurological signs postoperatively (5.5%), with 3 (2%) patients who presented permanent stroke confirmed by computed tomography scan. One of these patients presented dysarthria, which disappeared after 3 months of neurological rehabilitation, while 5 other patients had transient ischaemic attack, which completely disappeared at discharge.
Thirty-six (24.8%) patients required transfusions, 32 (22%) patients received a permanent pacemaker. One patient developed a neck haematoma and surgical exploration was required for haemostasis. We encountered 1 case of late asymptomatic carotid dissection measuring 4 cm in length, found on postoperative Doppler ultrasound, which was followed up and remained asymptomatic after 2 years.
The mean length of hospital stay was 11 days. Echocardiography at discharge showed 27 (18.6%) patients with severe paravalvular prosthesis regurgitation (Grade 2 or higher) (Fig. 2) . Mean gradients at discharge were 7.2 ± 9 mmHg.
No other TAVI-related complications were encountered.
DISCUSSION
Available data from randomized controlled trials and large registries in elderly patients at increased surgical risk show that TAVI is superior in terms of mortality to medical therapy in extremerisk patients [1] , non-inferior or superior to surgery in high-risk patients [11] [12] [13] and non-inferior to surgery and even superior when transfemoral access is possible in intermediate-risk patients [14, 15] . The results of our series indicate that TCAVI is feasible in patients with poor femoral arterial access. Early mortality rates are acceptable in this high-risk population, with an overall 30-day mortality of 6.25%. We encountered minimal access complications at the carotid access site. The distance between the entry point and the aortic valve is short, which increases stability during aortic valve delivery and improves speed and accuracy. The access is very simple and can be performed with extreme simplicity and safety, because the artery is exposed and closed using experienced vascular technique. The transverse incision provides cosmetic benefit with minimal residual scarring. We TIA/cerebral stroke (n = 8) 5.5% Localized carotid dissection, asymptomatic (n = 1) 0.6% PPM implantation (n = 32) 22.2% Infection complication (n = 6) 4.1% Bleeding complication (n = 37) 25,6% Hospital stay (days)
11.7 ± 6.6
PPM: permanent pacemaker implantation; TIA: transient ischaemic attack.
never used carotid bypass or shunting. Using this approach, TCAVI patients experienced a rate for all strokes and transient ischaemic attack of 5.5%, which is similar, compared with other vascular accesses. This rate is comparable to the PARTNER 2A trial [14] , which reports a stroke rate of 6.4% at 30 days for the TAVI group and 6.5% for the surgical group and is similar to the SURTAVI clinical trial, which reports 4.5% in the TAVI group and 6.5% in the surgical group at 30 days [15] . Similarly, the SOURCE registry demonstrated only a 2.6% incidence of stroke in 574 trans apical (TA) patients at 30 days [16] .
We never had to convert to another approach, and no vascular complications were encountered.
The carotid approach can also be easily performed in patients with limited pulmonary reserve and/or with poor ejection fraction, because no purse string is placed on the heart and no thoracotomy is performed. A self-expandable valve was used in 83% of cases, and this was related to the experience and the choice of each team. This can explain the relatively high rate of PPM (22%) in our study, which is similar to the SURTAVI clinical trial rate of 26% [15] .
The rate of transfusion is close to 25%, which is not related to bleeding complications at the neck site, beacuse only 1 patient developed a neck haematoma, which had to be reoperated. It mostly is related to the decision made by the teams to transfuse patients if haemoglobin is less than 10 g/dl in these elderly patients. This rate is similar to the GARY registry transfusion rate, which is 25% in the TAVI group and 45% in the sAVR group [11] , or the SURTAVI clinical trial, which is 12% in the TAVI and 41% in the sAVR [15] .
In randomized trial, TAVI was shown to be superior to standard medical therapy in a cohort of inoperable patients and noninferior to aortic valve replacement in high-risk, operable patients [1, 12] . If the femoral access remains our preferred method, because it can be performed entirely percutaneously, TCAVI currently represents 50% of our alternative route access, the other being the transapical approach.
The transapical approach has been extensively described, and its results are well known. It provides direct access to the aortic valve and can be performed rapidly. Its morbidity and mortality are, however, consistently superior to femoral access not only due to the differences in comorbidities but also due to specific complications related to thoracotomy access (pleural effusion, pain and decreased ventilation). In the PARTNER trial, patients not suitable for transfemoral trans aortic valve replacement (TAVR) were randomly assigned to either transapical implantation [premarket approval transapical (PMA-TA)] or conventional surgery sAVR. After completion of the trial, patients were enrolled into a nonrandomized continued access cohort [18] . Thirty-day or in-hospital mortality was 10.6% for the PMA-TA group, 12% for the sAVR group, 8.8% for the NRCA-TA group and 10% in the SOURCE report, which is higher than our mortality rate of 6.3% [16] .
The transaortic approach has also been described and provides direct access to the aorta through a minimal approach. Its limitations result from the size of the aorta, which should be at least 8 cm from the aortic valve to the point of entry of the delivery sheath, with the risk of aortic dissection and pain from the incision.
The subclavian approach is also a simple vascular access, which can be difficult to perform due to the tortuosity and the small calibre of the artery. Also, the right subclavian approach offers a more difficult access due to the sharp angle of the aortic root. Finally, the right subclavian approach can be a source of increased transient ischaemic attack or strokes, due to the possible embolization of the vertebral and left carotid in the aortic arch. In addition, it should not be used when a left internal mammary bypass is patent on a coronary artery.
Therefore, TCAVI is a purely vascular access site, with minimal complications and is technically very simple. Its careful evaluation compared with alternative routes should be performed, but initial results are encouraging, with a low rate of complications and ease of performance. Careful selection of patients is required before performing this technique to avoid major complications.
Limitations
The main limitations to this study relate to its retrospective nature and the small number of patients; however, to the best of our knowledge, this is, overall, the largest series of consecutive TCAVI cases published so far.
